Literature DB >> 10051464

Chronic unexplained hypertransaminasemia may be caused by occult celiac disease.

M T Bardella1, M Vecchi, D Conte, E Del Ninno, M Fraquelli, S Pacchetti, E Minola, M Landoni, B M Cesana, R De Franchis.   

Abstract

In a subset of patients attending liver units, a chronic increase in serum transaminases may remain of undetermined cause despite thorough investigations. On the other hand, elevated levels of serum transaminases have been reported in about 40% of adult celiac patients. To evaluate the prevalence of subclinical celiac disease in patients with chronic unexplained hypertransaminasemia in comparison with that in the general population (0.5%), 140 consecutive patients with chronic increases of serum transaminases levels of unknown cause were tested for antigliadin and antiendomysium IgA antibodies. All patients with positive antibody tests were offered upper gastrointestinal endoscopy with distal duodenal biopsy. Thirteen patients (9.3%, 95% confidence interval 5. 0-15.4) had positive antigliadin and antiendomysium antibodies. The prevalence of antibodies was 17% in women and 5.4% in men (8/47 vs. 5/93 respectively; relative risk 3.2, 95% confidence interval 1.1-9. 1). Distal duodenal biopsy performed in all but one of the patients showed mild villous atrophy with increased intraepithelial lymphocytes in three cases, subtotal villous atrophy in six, and total villous atrophy in three. The prevalence of celiac disease in the patient group was significantly higher than that in the general population (P <.001) with a relative risk of 18.6 (95% confidence interval 11.1-31.2). On the basis of the present findings, screening for celiac disease is an important tool in the initial diagnostic work-up of patients with chronic unexplained hypertransaminasemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051464     DOI: 10.1002/hep.510290318

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

Review 1.  Evaluation of abnormal liver function tests.

Authors:  J K Limdi; G M Hyde
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

2.  Systemic autoimmune disorders associated with celiac disease.

Authors:  Jason Slate; Perry Hookman; Jamie S Barkin; Richard S Phillips
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 3.  Hepatobiliary and pancreatic disorders in celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

4.  Abnormal liver tests as an initial presentation of celiac disease.

Authors:  Michael Sifford; Alvaro Koch; Eun Lee; Luis R Peña
Journal:  Dig Dis Sci       Date:  2007-05-26       Impact factor: 3.199

5.  The changing face of celiac disease.

Authors:  R Lad; K Jacobson
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

6.  Celiac disease suspected at endoscopy in patients with chronic liver disease.

Authors:  Rakesh Kochhar; Usha Dutta; Amit Miglani; Suraj Bhagat; Kuchhangi Sureshchandra Poornachandra; Kim Vaiphei; Chander K Nain; Kartar Singh
Journal:  Indian J Gastroenterol       Date:  2011-08-17

7.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 8.  The Liver and Celiac Disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Clin Liver Dis       Date:  2019-03-01       Impact factor: 6.126

Review 9.  Coeliac disease and liver dysfunction.

Authors:  S Davison
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

10.  Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population.

Authors:  Natalia E Castillo; Rohini R Vanga; Thimmaiah G Theethira; Alberto Rubio-Tapia; Joseph A Murray; Javier Villafuerte; Alan Bonder; Rupa Mukherjee; Joshua Hansen; Melinda Dennis; Ciaran P Kelly; Daniel A Leffler
Journal:  Am J Gastroenterol       Date:  2015-07-07       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.